Skip to Content

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

By RAF CASERT
Associated Press

BRUSSELS (AP) — The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators. The 27-nation bloc already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. Now, EU antitrust Commissioner Didier Reynders says the order Thursday to unwind the deal “restores competition in the development of early cancer detection tests.” He added that the move also ensures “a level playing field in this crucial market to the ultimate benefit of European consumers.”

Article Topic Follows: AP National

Jump to comments ↓

Author Profile Photo

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content